Plain-English translation of NCT04601428 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CSR02-Fab-TF that is injected directly into the blood vessels feeding liver cancer tumors. The medication was designed based on a discovery that liver cancer blood vessels have a special protein that normal liver blood vessels don't have — the new treatment recognizes this protein and causes blood clots to form in the tumor's blood supply, starving the cancer of nutrients and oxygen.
Many people with intermediate or advanced liver cancer stop responding to standard treatments like chemotherapy or radiation, and their cancer continues to grow. This medication offers a new approach by targeting the tumor's blood vessels directly rather than the cancer cells themselves, potentially helping patients whose cancers have become resistant to other therapies.
You will receive the medication through a procedure where a catheter (thin tube) is placed into the blood vessel feeding your liver tumor, and the treatment is injected directly into that vessel. The study will start with a low dose and gradually increase doses in subsequent patients to find the safest and most effective level. You'll have blood tests and imaging scans to monitor how your tumor responds and to watch for any side effects.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Taiwan